Zhong Guo Ji Jin Bao·2025-08-11 13:29Core Viewpoint - The long-term service contract between Beijing University Pharmaceutical's wholly-owned subsidiary and Peking University International Hospital will terminate in May 2025, leading to significant operational challenges for the company [1][3]. Group 1: Business Impact - The termination of the contract is expected to result in a revenue decrease of approximately 600 million yuan (29.13% of the latest audited revenue) and a net profit decrease of about 40 million yuan (28.99% of the latest audited net profit) starting from June 2025 [3]. - From 2026 onwards, the company may face a revenue reduction of around 1.027 billion yuan (49.85% of the latest audited revenue) and a net profit decrease of approximately 68.69 million yuan (49.78% of the latest audited net profit) [3][5]. Group 2: Strategic Adjustments - The company is exploring new directions for the transformation of its subsidiary to mitigate the impact of the contract termination, although the success of this transformation remains uncertain [5]. - A strategic adjustment of the production and manufacturing system is proposed to enhance operational efficiency and core competitiveness, focusing on establishing a manufacturing subsidiary [6]. Group 3: Corporate Identity Changes - The company is initiating a name change process to gradually achieve a "de-Peking University" status, following changes in its actual controlling shareholder [7]. - The company primarily engages in the research, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services [7]. Group 4: Market Position - As of August 11, the company's stock price was 6.93 yuan per share, with a total market capitalization of 4.1 billion yuan [8].